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ABSTRACT
Introduction: Linagliptin is a xanthine-based
dipeptidyl peptidase (DPP)-4 inhibitor that is
now available in numerous countries worldwide
for the treatment of type 2 diabetes mellitus
(T2DM). The aim of this study was to evaluate
further the mechanisms underlying the
improvements in glycemic control observed
with linagliptin. The effects of linagliptin on
DPP-4, pharmacodynamic parameters, and
glycemic control versus placebo were assessed
in patients with inadequately controlled T2DM.
Methods: Patients in this phase 2a, multicenter,
randomized, double-blind, placebo-controlled
study received placebo (n = 40) or linagliptin
5 mg (n = 40). Sitagliptin 100 mg (n = 41) once
daily for 4 weeks was included for exploratory
purposes. Primary endpoints for linagliptin versus
placebo: change from baseline to day 28 in 24-h
weighted mean glucose (WMG) and intact
glucagon-like peptide (GLP)-1 area under the
time–effect curve between 0 and 2 h (AUEC0–2h)
following meal tolerance test on day 28.
Results: Linagliptin increased intact GLP-1
AUEC0–2h (?18.1 pmol/h/L) and lowered 24-h
WMG (-1.1 mmol/L) versus placebo (both
P\0.0001) after 28 days. Intact glucose-
dependent insulinotropic polypeptide increased
in line with GLP-1 (?91.4 pmol/h/L
increase vs. placebo; P\0.0001). Glycated
hemoglobin (-0.22%; P = 0.0021), fasting
plasma glucose (-0.6 mmol/L; P = 0.0283), and
glucose (AUEC0–3h) (-5.9 mmol/h/L; P\0.0001)
improved significantly with linagliptin versus
placebo. Most adverse events were mild;
hypoglycemia or serious adverse events were
not reported. Sustained DPP-4 inhibition
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(C80%) throughout the treatment period
was accompanied by significant reductions
in glucagon starting at day 1 of linagliptin
administration.
Conclusion: Linagliptin was well tolerated and
effectively inhibited plasma DPP-4 activity in
patients with T2DM, producing immediate
improvements in incretin levels, glucagon
suppression, and glycemic control that were
maintained throughout the study period.
Keywords: Dipeptidyl peptidase-4 inhibitors;
Glucagon; Glucagon-like peptide-1; Glycemic
control; Linagliptin; Type 2 diabetes mellitus
INTRODUCTION
Dipeptidyl peptidase (DPP)-4 inhibitors are oral
antidiabetic agents that act by inhibiting the
degradation of the gastrointestinal incretin
hormones, glucagon-like peptide (GLP)-1 and
glucose-dependent insulinotropic polypeptide
(GIP), by the DPP-4 enzyme [1, 2]. The resulting
increase in availability of these hormones
stimulates glucose-dependent insulin release
from pancreatic beta cells, while reducing
glucagon output from pancreatic alpha cells [3].
Although there is no consensus on the best
choice of antihyperglycemic agent for patients
in whom metformin fails to maintain glycemic
control, it has been suggested that the addition
of a DPP-4 inhibitor may be appropriate, as
these compounds seem to have a similar effect
on glycated hemoglobin (HbA1c) compared
with sulfonylureas or thiazolidinediones, but
without the risk of hypoglycemia or weight
gain [4].
Linagliptin is a xanthine-based DPP-4
inhibitor that is now available in numerous
countries worldwide for the treatment of type 2
diabetes mellitus (T2DM). Like most DPP-4
inhibitors, the pharmacological features of
linagliptin permit once daily dosing, without
the need for dose titration [5, 6]. However,
unlike other DPP-4 inhibitors, the excretion of
linagliptin is largely via the bile and gut and,
therefore, dose adjustment is not required in
patients with declining renal function [7, 8].
Several clinical trials have demonstrated that
linagliptin elicits reductions in HbA1c, fasting
plasma glucose (FPG), and postprandial glucose
(PPG) in patients with T2DM [6, 9–13].
The aim of the present study was to explore
further the mechanisms underlying the




Patients aged between 18 and 80 years, with a
body mass index of 40 kg/m2 or less at
screening, who were either treatment naive or
had previously received monotherapy with oral
antidiabetic agents and whose HbA1c level was
between 6.5% (C47.4 mmol/mol) and 10.0%
(B85.8 mmol/mol) were eligible.
The main exclusion criteria included
myocardial infarction, stroke, or transient
ischemic attack within 6 months before
enrollment; impaired hepatic function; renal
insufficiency; hypersensitivity or allergy to
linagliptin, sitagliptin, or excipients; or
treatment with rosiglitazone, pioglitazone,
GLP-1 analogs, insulin, DPP-4 inhibitors, or
anti-obesity drugs during the previous 3 months.
An independent ethics committee
(A¨rztekammer Nordrhein, Du¨sseldorf, Germany)
approved the study, which was conducted
according to the Declaration of Helsinki and
the International Conference on Harmonisation
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harmonised tripartite guideline for good clinical
practice. All patients gave written, informed
consent to participate.
Study Design
This phase 2a, multicenter, randomized, double-
blind, double-dummy, placebo-controlled,
parallel-group study compared oral linagliptin
(5 mg once daily) with placebo. While a
sitagliptin arm (100 mg orally once daily) was
included as a ‘‘positive control’’, the study
was not statistically powered to compare the
linagliptin and sitagliptin arms.
Patients already taking one oral antidiabetic
medication underwent a 2-week washout. All
patients underwent a 2-week, open-label,
placebo run-in, followed by a 4-week treatment
period with linagliptin, sitagliptin, or placebo.
Post-treatment follow-up lasted 2 weeks.
Patients were randomly assigned using an
interactive voice response system, stratified by
HbA1c at the beginning of the placebo run-in
[\8.5% vs. C8.5% (\69.4 vs. C69.4 mmol/mol)]
and previous use of antidiabetic drugs.
Sitagliptin was over-encapsulated to
maintain blinding of treatment allocation.
Study Assessments
Baseline measurements were made on day -1
(the day before randomization), and the study
assessments [including meal tolerance test
(MTT)] were performed on days 1, 28, 29,
and 30. Repeated blood samples were taken
to obtain blood glucose and hormone
measurements, as described in detail later.
Longer-term markers of blood glucose control
were evaluated on days -1, 15, 28, and 42.
The MTT consisted of two nutrition bars
(which, together, provided 300 kCal, and
contained 13 g protein, 40 g carbohydrate, and
10 g fat) and a high energy, high protein drink
(which provided 300 kCal, and contained 16 g
protein, 90 g carbohydrate, and 6 g fat). Markers
determined after each MTT included plasma
glucose, intact GLP-1, intact GIP, glucagon,
insulin, and C-peptide levels. Longer-term
markers of glycemic control included HbA1c,
fructosamine, and 1,5-anhydroglucitol.
Plasma glucose was measured electrochemically
with a biosensor-based assay (Super GL, Hitado,
Mo¨hnesee-Delecke, Germany). Intact GLP-1 was
measured by a fluorescence-based enzyme-linked
immunosorbent assay, using a Linco research
system (Linco Research Inc., St Charles, MO, USA)
instrument. Plasma DPP-4 levels were determined
using a semiquantitative enzyme activity assay with
fluorescence detection, which has been described
previously [14].
Levels of intact GIP and HbA1c were
measured as described previously [15–17].
International Federation of Clinical Chemistry
values for HbA1c were converted from
percentages to mmol/mol. Glucagon, insulin,
and C-peptide levels were analyzed using
specific immunoassays. Levels of fructosamine
and 1,5-anhydroglucitol were measured using
specific enzymatic assays.
Throughout the study, safety was assessed
based on adverse event frequencies and
severities, vital signs, 12-lead electrocardiogram,
physical examination, and laboratory tests.
Endpoints
The primary assessments, after 28 days of
treatment, were change from baseline in
weighted mean glucose (WMG), and change
from baseline in the area under the time–effect
curve between 0 and 2 h (AUEC0-2h) for GLP-1
following a MTT. The secondary assessments
were change in FPG from baseline to day 28, and
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change in plasma glucose (AUEC0-3h) following
a MTT from baseline to day 28.
Additional pharmacodynamic assessments
included levels of intact GIP, glucagon, insulin,
C-peptide, 2-h PPG, and inhibition of plasma
DPP-4.
Areas under the curves were determined with
the trapezoidal rule. For WMG, the area under
the glucose concentration–time curve over 24 h
was divided by 24.
Statistical Analyses
The primary, secondary, and other quantitative
pharmacodynamic endpoints were evaluated
using an analysis of covariance model with
treatment as the fixed effect. For each endpoint,
the corresponding baseline value (obtained at
day -1) was included in the model as a linear
covariate. The variables, previous use of
antidiabetic agents, and HbA1c [\8.5% vs. C8.5%
(\69.4 vs. C69.4 mmol/mol)] at baseline, were
included in the model, as the randomization was
stratified using these parameters. Testing of
superiority of linagliptin versus placebo for the
primary and secondary endpoints after 4 weeks of
treatment was performed (one-sided at the 0.025
level). The Wilcoxon–Mann–Whitney test was
used for treatment comparisons of DPP-4
inhibition, and Hodges–Lehmann estimates for
the median differences and their confidence
intervals (CIs).
For sample size estimation, the placebo-
adjusted change from baseline in WMG was
assumed to be -17.2 mg/dL (0.95 mmol/L),
with a SD of 22.6 mg/dL (1.25 mmol/L) (based
on a study by Brazg et al. [18]). Lower variability
was assumed for the other primary endpoint,
GLP-1 AUEC0–2h. Based on these assumptions,
38 completers per treatment arm were needed
to achieve a power of 90% for the change in
WMG, whereas the power was greater than 98%
for GLP-1 AUEC0–2h.
A per protocol set of patients was created
for analyses of the primary and secondary
endpoints to compare linagliptin with placebo.
In addition, an exploratory analysis was
performed using the data obtained from subjects
receiving sitagliptin treatment. However, the trial
was not designed or sufficiently powered to
compare the efficacy or tolerability of linagliptin
with sitagliptin.
RESULTS
Demographic and Baseline Characteristics
Demographic and baseline characteristics were
similar across the patient groups. The mean (SD)
baseline values for HbA1c were 7.3% (0.53%),
and for FPG were 9.25 (1.53) mmol/L. Diabetes
medications used previously (67.8% of patients)
were metformin (55.4%), sulfonylureas (9.1%),
and glinides (3.3%). A total of 121 patients
was randomly assigned (40 to placebo, 40
to linagliptin, and 41 to sitagliptin). Three
patients (2.5%) withdrew from the study
prematurely: two patients in the placebo arm
who experienced hyperglycemia, and one
patient in the linagliptin group for whom
there was difficulty in obtaining blood
samples. One subject in the placebo group had
a protocol violation that was considered to be
important during blinded review (incorrect
timing of administration of trial medication).
The analysis of secondary, but not the primary,
endpoints excluded this patient and was
performed using data obtained from the 117
patients who completed the study without
relevant protocol violations. Data on
demographics, baseline characteristics, and
safety were derived from the complete patient
set (n = 121).
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Primary and Secondary Endpoints
After 4 weeks of treatment, linagliptin elicited
decreases in 24-h WMG and increases in GLP-1
AUEC0–2h (Table 1). These changes were
significantly larger than those seen with
placebo (P\0.0001 for all comparisons).
Likewise, linagliptin achieved significant
placebo-corrected changes from baseline for
FPG and for glucose AUEC0–3h.
Inhibition of DPP-4
Median DPP-4 inhibition achieved by
linagliptin treatment at trough was 79.8%
at day 2 (24 h after the first dose). DPP-4
inhibition by linagliptin was then sustained at
80% or greater throughout the treatment
period. On day 28, median DPP-4 inhibition at
trough was 82.2% for linagliptin and 70.3% for
sitagliptin (estimate of median difference:
12.6%; 95% CI 9.5% to 15.7%; P\0.0001). Two
weeks after the last dose of linagliptin to plasma
DPP-4 was still inhibited by approximately 17%.
Effects on Incretins and Other Peptide
Hormones
Linagliptin therapy increased placebo-corrected
intact GIP AUEC0–2h by approximately 1.5-fold on
day 1 (from a baseline value of 129.9 ± 9.0 pmol/h)
with approximately a two-fold increase observed on
day 28 (Table 2). Data for intact GLP-1 AUEC0–2h on
day1were in linewiththesedata, showing increases
of similar magnitude on days 1 and 28 (Tables 1 and
2). Placebo-corrected levels of glucagon decreased
significantly on days 1 and 28 with linagliptin. For
insulin and C-peptide, changes from baseline were
not significant.
Following a MTT on day 28, mean plasma
concentrations of intact GLP-1 increased in
the linagliptin-treated group compared with
placebo, at all time points evaluated (Fig. 1).
In line with these changes, mean plasma
glucagon levels were reduced in the
linagliptin-treated group versus placebo.
Effects on Plasma Glucose Parameters
The placebo-adjusted changes from baseline of
plasma glucose parameters following linagliptin
therapy were statistically significant on days 1
and 28, including 2-h PPG, peak glucose,
glucose AUEC0–3h, and 24-h WMG (Tables 1
and 2). For FPG, the placebo-adjusted change
from baseline was not significant on day 1 but
reached statistical significance on day 28.
Placebo-adjusted means for HbA1c showed
a nonsignificant reduction on day 15 and
significant reductions on days 28 (Table 2)
and 42 (-0.28%; 95% CI -0.42 to -0.13;
P = 0.0003). Fructosamine showed a significant
reduction from baseline on day 28, but not on
day 15 of treatment (Table 2) or at 2 weeks post-
treatment (day 42) (-5.1 lmol/L; 95% CI -16.8
to 6.5; P = 0.3848). There were significant
increases from baseline in 1,5-anhydroglucitol
levels on days 15 and 28 (Table 2), but at
2 weeks post-treatment (day 42) the increase
was not statistically significant (0.8 lg/mL; 95%
CI -1.0 to 2.6; P = 0.3634).
The 24-h glucose profile, evaluated on day
28, showed that linagliptin was associated with
lower mean plasma glucose concentrations at
all time points, compared with placebo (Fig. 1).
Results obtained on days 29/30 were
essentially similar; therefore, only data from
day 28 are presented.
Exploratory Analyses: Linagliptin
versus Sitagliptin
Additional exploratory sensitivity analyses,
including all three study treatments, compared
Diabetes Ther (2012) 3:10 Page 5 of 14
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the effects of linagliptin (n = 39) and sitagliptin
(n = 40) on the primary and secondary
endpoints, between baseline and day 28. The
reduction of WMG was numerically greater
with sitagliptin compared with linagliptin on
day 28 (difference of 0.3 ± 0.2 mmol/L; 95% CI
-0.1 to 0.8; P = 0.1274). The corresponding
increase in intact GLP-1 AUEC0–2h was
numerically greater with linagliptin than with
sitagliptin (difference of 2.8 ± 2.7 pmol/h/L;
95% CI -2.7 to 8.2; P = 0.3130). For FPG
and glucose AUEC0–3h, the reductions were
numerically greater for sitagliptin versus
linagliptin, with differences of 0.3 ± 0.2 mmol/
L (95% CI -0.2 to 0.8; P = 0.2281) and
1.3 ± 1.0 mmol/h/L (95% CI -0.8 to 3.3;
Table 1 Primary (changes in WMG and GLP-1 AUEC0–2h) and secondary (changes in FPG and glucose AUEC0–3h)




Baseline mean (SE) 10.6 (0.3) 10.5 (0.4)
Adjusted mean change from baseline (SE) 0.01 (0.2) -1.1 (0.2)
Comparison vs. placebo: adjusted mean change (95% CI) – -1.1 (-1.6, -0.7)
P-value – \0.0001
Intact GLP-1 AUEC0–2h (pmol/h/L)
Baseline mean (SE) 15.0 (1.9) 17.4 (1.8)
Adjusted mean change from baseline (SE) 0.4 (2.1) 18.5 (2.1)




Baseline mean (SE) 9.4 (0.2) 9.2 (0.2)
Adjusted mean change from baseline (SE) -0.01 (0.2) -0.6 (0.2)
Comparison vs. placebo: adjusted mean change (95% CI) – -0.6 (-1.1, -0.1)
P-value – 0.0283
Glucose AUEC0–3h (mmol/h/L)
Baseline mean (SE) 40.1 (1.2) 40.4 (1.3)
Adjusted mean change from baseline (SE) 0.4 (0.8) -5.5 (0.8)
Comparison vs. placebo: adjusted mean change (95% CI) – -5.9 (-8.2, -3.7)
P-value – \0.0001
AUEC area under the time–effect curve, CI conﬁdence interval, FPG fasting plasma glucose, GLP-1 glucagon-like peptide-1,
SE standard error, WMG weighted mean glucose
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Table 2 Exploratory endpoints: baseline values (day –1) and adjusted mean changes from baseline on days 1, 15, and 28
(where data available)
Day 1 Day 15 Day 28
Placebo Linagliptin Placebo Linagliptin Placebo Linagliptin
Intact GLP-1 AUEC0–2h (pmol/h/L)
Baseline (SE) 14.6 (1.9) 17.4 (1.8) – –
See Table 1Mean change from baseline 0.8 11.3 – –
Comparison vs. placebo (95% CI) – 10.5 (6.5, 14.6) – –
P-value – \0.0001 – –
Intact GIP AUEC0–2h (pmol/h/L)
Baseline (SE) 105.2 (7.2) 129.9 (9.0) – – 105.2 (7.2) 129.9 (9.0)
Mean change from baseline 28.7 69.5 – – 15.2 106.6
Comparison vs. placebo (95% CI) – 40.7 (13.9, 67.5) – – – 91.4 (67.0, 115.8)
P-value – 0.003 – – – \0.0001
Total GIP AUEC0–2h (pmol/h/L)
Baseline (SE) 239.6 (18.1) 301.4 (21.2) – – 239.6 (18.1) 301.4 (21.2)
Mean change from baseline 50.5 -82.8 – – 12.6 -94.0
Comparison vs. placebo (95% CI) – -133.3 (-186.6, -80.0) – – – -106.7 (-147.9, -65.4)
P-value – \0.0001 – – – \0.0001
Insulin AUEC0–2h (mU/h/L)
Baseline (SE) 87.6 (6.9) 100.6 (8.5) – – 87.6 (6.9) 102.4 (8.2)
Mean change from baseline 19.7 15.5 – – 7.2 -0.7
Comparison vs. placebo (95% CI) – -4.3 (-19.1, 10.6) – – – -8.0 (-22.3, 6.4)
P-value – 0.57 – – – 0.27
C-peptide AUEC0–2h (pmol/h/L)
Baseline (SE) 4,515.0 (212.7) 5,081.0 (232.4) – – 4,515.0 (212.7) 5,161.4 (238.5)
Mean change from baseline 716.7 394.4 – – -121.6 -146.5
Comparison vs. placebo (95% CI) – -322.3 (-684.7, 40.1) – – – -24.8 (-445.7, 396.0)
P-value – 0.08 – – – 0.91
Glucagon AUEC0–2h (pg/h/mL)
Baseline (SE) 183.0 (11.5) 182.1 (6.6) – – 183.0 (11.5) 182.1 (6.6)
Mean change from baseline 17.3 -6.1 – – 1.3 -17.4
Comparison vs. placebo (95% CI) – -23.4 (-36.8, -10.1) – – – -18.7 (-37.0, -0.4)
P-value – 0.0008 – – – 0.0452
2-h PPG (mmol/L)
Baseline (SE) 14.6 (0.6) 14.8 (0.6) – – 14.6 (0.6) 14.8 (0.6)
Mean change from baseline -0.2 -1.3 – – 0.1 -2.3
Comparison vs. placebo (95% CI) – -1.1 (-1.9, -0.3) – – – -2.4 (-3.5, -1.3)
P-value – 0.009 – – – \0.0001
Peak glucose (mmol/L)
Baseline (SE) 15.8 (0.5) 15.9 (0.5) – – 15.8 (0.5) 15.9 (0.5)
Mean change from baseline 0.2 -1.5 – – 0.04 -2.2
Comparison vs. placebo (95% CI) – -1.7 (-2.4, 1.0) – – – -2.2 (-3.2, 1.3)
P-value – \0.0001 – – – \0.0001
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Table 2 continued
Day 1 Day 15 Day 28
Placebo Linagliptin Placebo Linagliptin Placebo Linagliptin
FPG* (mmol/L)
Baseline (SE) 9.5 (0.2) 9.2 (0.2) 9.5 (0.2) 9.2 (0.2)
See Table 1Mean change from baseline 0.09 0.03 0.2 -0.5
Comparison vs. placebo (95% CI) – -0.1 (-0.6, 0.4) – -0.6 (-1.1, -0.2)
P-value – 0.7952 – 0.01
Glucose AUEC0–3h (mmol/h/L)
Baseline (SE) 40.2 (1.3) 40.4 (1.4) – –
See Table 1Mean change from baseline 0.3 -3.0 – –
Comparison vs. placebo (95% CI) – -3.3 (-4.8, -1.7) – –
P-value – 0.0001 – –
24-h WMG (mmol/L)
Baseline (SE) 10.6 (0.3) 10.5 (0.4) – –
See Table 1Mean change from baseline 0.04 -0.5 – –
Comparison vs. placebo (95% CI) – -0.5 (-0.7, -0.3) – –
P-value – \0.0001 – –
HbA1c (%)
Baseline (SE) – – 7.42 (0.1) 7.31 (0.1) 7.42 (0.1) 7.31 (0.1)
Mean change from baseline – – -0.10 -0.15 -0.06 -0.27
Comparison vs. placebo (95% CI) – – – -0.05 (-0.14, 0.05) – -0.22 (-0.35, -0.08)
P-value – – – 0.31 – 0.002
HbA1c, mmol/mol, IFCC
Baseline (SE) – – 57.6 (1.1) 56.4 (1.1) 57.6 (1.1) 56.4 (1.1)
Mean change from baseline – – -1.1 -1.6 -0.7 -3.0
Comparison vs. placebo (95% CI) – – – -0.5 (-1.5, 0.5) – -2.4 (-3.8, -0.9)
P-value – – – 0.31 – 0.002
Fructosamine (lmol/L)
Baseline (SE) – – 257.2 (6.4) 255.1 (5.4) 257.6 (6.2) 257.6 (6.1)
Mean change from baseline – – 17.0 9.0 2.9 -6.1
Comparison vs. placebo (95% CI) – – – -7.9 (-17.6, 1.8) – -9.0 (-17.9, -0.2)
P-value – – – 0.1069 – 0.0446
1,5-Anhydroglucitol (lg/mL)
Baseline (SE) – – 9.3 (1.0) 10.2 (1.1) 9.3 (1.0) 9.9 (1.0)
Mean change from baseline – – -0.5 0.8 -0.8 1.0
Comparison vs. placebo (95% CI) – – – 1.3 (0.8, 1.8) – 1.8 (1.0, 2.5)
P-value – – – \0.0001 – \0.0001
Data shown are adjusted mean change from baseline
* FPG measured on day 2
– no data available
AUEC area under the time–effect curve, CI conﬁdence interval, FPG fasting plasma glucose, GIP glucose-dependent insulinotropic polypeptide, GLP-1 glucagon-like peptide-1,
HbA1c glycated hemoglobin, IFCC international federation of clinical chemistry, PPG postprandial glucose, SE standard error, WMG weighted mean glucose
Page 8 of 14 Diabetes Ther (2012) 3:10
123
P = 0.2230), respectively. None of the observed
differences between linagliptin and sitagliptin,
for primary and secondary endpoints, were
statistically significant.
Safety and Tolerability
The safety analysis comprised 121 patients
who had received at least one dose of trial
medication. Forty-three patients (35.5%)
experienced at least one adverse event during
the study (Table 3). However, most adverse
events were mild and there were no severe or
serious adverse events; no adverse events led to
treatment discontinuation. During the washout
phase, one patient experienced two severe
adverse events that were not considered to be
treatment related (aggravated migraine and a
panic attack that required hospitalization).
Headache, back pain, and nasopharyngitis
were the most frequently reported adverse
events. Drug-related adverse events occurred in
one patient (2.5%) in the placebo group (upper
abdominal pain), two patients (5.0%) in
the linagliptin-treated group (headache and
hyperhydrosis), and five patients (12.2%) in
the sitagliptin-treated group [headache (two
patients), hot flush, abdominal distension,
Fig. 1 24-h proﬁle of mean plasma glucose (a), changes in
intact GLP-1 (b), intact GIP (c), and glucagon over 2.5 h
following a meal tolerance test (d), for subjects allocated to
the linagliptin or placebo arms (day 28). Data are shown as
mean ± standard error. Time point 0, shown at the start
of the weighted mean glucose interval, corresponds to
approximately 8:00 a.m. GIP glucose-dependent insulino-
tropic polypeptide, GLP glucagon-like peptide
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rhinorrhea, and dry mouth]. Hypoglycemia
was not reported in any treatment group. No
clinically relevant changes in vital signs were
observed.
DISCUSSION
This study provides the most detailed
comparison to date of the acute and longer-
term effects of linagliptin on glycemic control
in patients with insufficiently controlled T2DM.
In this study, orally administered linagliptin,
5 mg once daily, significantly improved 24-h
glycemic control compared with placebo, as
indicated by a reduction in plasma WMG levels.
Twenty-four hours after the first dose of
linagliptin, median DPP-4 inhibition was
approximately 80%, which has previously
been proposed as the threshold for effective
glycemic control [19]. Inhibition of DPP-4 was
sustained throughout the 4-week study, with a
low level (17%) detectable even 2 weeks after
the end of linagliptin administration. These
findings are consistent with stable binding of
linagliptin to DPP-4 and the long terminal half-
life of the drug (128–184 h in healthy
individuals) [14].
In accordance with these findings, linagliptin
improved HbA1c levels and longer-term markers
of glycemic control, i.e., fructosamine and 1,5-
anhydroglucitol levels. The effect on HbA1c was
maintained 2 weeks after treatment cessation. As
1,5-anhydroglucitol competes with glucose for
renal tubular reabsorption [20], it gives a better
reflection of postmeal glycemic excursions than
HbA1c or fructosamine [21, 22]. Indeed, in this
study, linagliptin primarily reduced PPG levels
rather than FPG; FPG was virtually unchanged
24 h after the first dose and moderately reduced
(a decrease of approximately 6% vs. baseline)
after 4 weeks. In contrast, after 4 weeks of
linagliptin administration, the change from
baseline in plasma glucose 2 h after MTT (PPG)
was 2.4 mmol/L (a decrease of approximately
15%). As the patients in this study had
reasonably good glycemic control (mean
baseline HbA1c was 7.30 ± 0.53%), this may be
a result of the glucose-dependent blood glucose-
lowering effect that has been observed with DPP-
4 inhibitors in general [3].
Medium-term markers of glycemic control
might be more appropriate than HbA1c to
evaluate the potential of linagliptin to
improve blood glucose control in a study with
a 4-week treatment duration. Nevertheless,




Number of patients 40 (100) 40 (100) 41 (100)
Total with adverse events 13 (32.5) 12 (30.0) 18 (43.9)
Headache 3 (7.5) 4 (10.0) 5 (12.2)
Back pain 2 (5.0) 3 (7.5) 1 (2.4)
Nasopharyngitis 1 (2.5) 2 (5.0) 2 (4.9)
Epistaxis 0 (0.0) 2 (5.0) 0 (0.0)
Arthralgia 0 (0.0) 2 (5.0) 0 (0.0)
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HbA1c was included in the efficacy parameters
following the recent findings of a significant
effect of linagliptin on HbA1c after 4 weeks of
treatment [9]. The results presented here seem
to be in accordance with previous studies;
Nonaka et al. [23] reported a placebo-adjusted
decrease in WMG of 1.4 mmol/L with
sitagliptin 100 mg in Japanese patients with
T2DM. In a mostly non-Asian population of
patients with T2DM with a slightly higher
baseline HbA1c (7.7 ± 0.8%; 57 ± 0.7 mmol/
mol), 4 weeks of treatment with sitagliptin,
added to a preexisting metformin therapy,
resulted in a placebo-adjusted decrease in
WMG of approximately 1 mmol/L [18]. HbA1c
was not reported in these studies in which
sitagliptin was evaluated over a treatment
period of 4 weeks; however, but the effect of
sitagliptin on HbA1c lowering in moderately
controlled (HbA1c \8%; 64 mmol/mol) elderly
patients over 12 weeks of treatment (0.5%) [24]
was not considerably greater than that observed
with linagliptin over only 4 weeks in the
present study (0.3%). Therefore, the observed
effect of linagliptin on HbA1c seems to be
within the range expected in patients with
fairly well-controlled T2DM.
Inhibition of DPP-4 by linagliptin, and the
resulting increases in GLP-1 levels, were
accompanied by changes in GIP and other
peptide hormones. The increased presence
of intact GLP-1 in plasma was also associated
with significant reductions in glucagon
(peak excursion and AUEC0–2h) from day 1
of linagliptin administration. Furthermore,
linagliptin produced significant reductions of
approximately 15% in peak glucagon (data not
shown) and approximately 10% in AUEC0–2h,
on both days 1 and 28.
It is well established that glucagon
secretion exhibits characteristic abnormalities
in T2DM. Frequently, patients have fasting
hyperglucagonemia and exaggerated responses
to meal tests [25]. GLP-1 is an inhibitor of
glucagon secretion and also retains this ability
in patients with T2DM [26]. It has recently been
suggested that the clinical importance of
the GLP-1-induced insulin stimulation and
glucagon inhibition contribute equally to the
glucose-lowering effect of GLP-1 in patients
with T2DM [27]. Therefore, it is fair to assume
that both the significant increase in GLP-1 and
the decrease in glucagon levels accounted for
the glucose-lowering potential of linagliptin in
this study.
Importantly, GLP-1 elevation by DPP-4
inhibitors does not impair the counterregulatory
response of glucagon to hypoglycemia [28].
Furthermore, linagliptin is associated with a
negligible risk of hypoglycemia when
administered as monotherapy. Indeed, no
patient developed symptomatic hypoglycemia
while receiving either of the DPP-4 inhibitors in
this study, confirming the low risk observed in
previous studies [6, 9, 14, 29–31].
The absence of any significant effects of
linagliptin administration on insulin and
C-peptide peak excursion or AUEC0–2h indicate
that insulin levels are maintained despite a
concomitant reduction in glucose levels. This
suggests improved responsiveness of the
pancreatic beta cells to glucose levels and an
insulinotropic effect. It is important to note that
GLP-1-mediated insulin secretion is glucose-
dependent and, as linagliptin reduced both the
peak excursion and AUEC0–3h of glucose within
1 day, the interpretation of insulin and C-peptide
data may need to take this into account. This
presumably explains why no changes in insulin
and C-peptide have been observed, and is in
accordance with previous studies that did not
find treatment-related changes in absolute
fasting and postprandial insulin levels or in
C-peptide levels [18, 32].
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At present, there are no published head-to-
head comparison studies between linagliptin
and sitagliptin. Although this trial was not
designed or sufficiently powered to compare
the efficacy of these two drugs, exploratory
analyses indicated no clinically or statistically
significant differences in the efficacy of these
two drugs, in terms of changes in 24-h WMG
and intact GLP-1, or secondary endpoints,
including FPG and glucose AUEC0–3h, after
28 days of treatment. This finding is consistent
with the authors’ observation of a similar extent
of DPP-4 inhibition by both linagliptin and
sitagliptin. It is also consistent with current
understanding of the mode of action of these
two drugs, which, as a result of DPP-4
inhibition, produce sustained increases in
GLP-1 levels, resulting in a lowering of plasma
glucose levels.
The safety findings in this study indicate that
linagliptin 5 mg once daily was well tolerated,
with an adverse event rate that was not higher
than that observed with placebo. Overall,
linagliptin and sitagliptin showed similar
efficacy and tolerability.
CONCLUSION
In summary, the findings of this study show that
linagliptin has a rapid onset of action in patients
with T2DM, producing potent inhibition of
DPP-4. This results in immediate and sustained
increases in both intact GLP-1 and GIP. Most
importantly, it results in statistically significant
and clinically meaningful improvements in
glycemic control that are similar to those
previously reported for other DPP-4 inhibitors
administered for a 4-week treatment period.
Linagliptin treatment was well tolerated, did
not cause hypoglycemia, and had an adverse
event rate that was similar to both placebo and
sitagliptin. Overall, linagliptin has shown similar
efficacy and tolerability compared with other
DPP-4 inhibitors. However, in contrast to other
agents of its class, linagliptin is mainly eliminated
unchanged via the bile and the gut, with little
reliance on renal excretion; consequently, it does
not require dose adjustment in patients with, or at
risk of, declining renal function.
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